Related references
Note: Only part of the references are listed.Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
Paolo Antonio Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy
Lawrence P. Andrews et al.
CLINICAL CANCER RESEARCH (2022)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al.
LANCET (2022)
A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)
M. H. H. Schuler et al.
ANNALS OF ONCOLOGY (2022)
Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
O. Hamid et al.
ANNALS OF ONCOLOGY (2022)
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
Simon J. Dovedi et al.
CANCER DISCOVERY (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
Kate J. Dixon et al.
CANCERS (2021)
Bispecific Antibodies to PD-1 and cTLA4: Doubling Down on T cells to Decouple efficacy from Toxicity
Elizabeth M. Burton et al.
CANCER DISCOVERY (2021)
Bispecific Antibodies: From Research to Clinical Application
Jiabing Ma et al.
FRONTIERS IN IMMUNOLOGY (2021)
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Aaron C. Tan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases
Mathieu Angin et al.
JOURNAL OF IMMUNOLOGY (2020)
1 Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
Dmitriy Zamarin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
Lawrence P. Andrews et al.
SCIENCE IMMUNOLOGY (2020)
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy et al.
CELL REPORTS MEDICINE (2020)
Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)
Caron A. Jacobson et al.
CANCER RESEARCH (2020)
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
Colm Keane et al.
BLOOD ADVANCES (2020)
Genomic and immunologic correlates of LAG-3 expression in cancer
Anshuman Panda et al.
ONCOIMMUNOLOGY (2020)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Defining 'T cell exhaustion'
Christian U. Blank et al.
NATURE REVIEWS IMMUNOLOGY (2019)
New emerging targets in cancer immunotherapy: the role of LAG3
Hannah Christina Puhr et al.
ESMO OPEN (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
Xinyi Guo et al.
NATURE MEDICINE (2018)
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Jonathan A. Trujillo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Lineage tracking reveals dynamic relationships of T cells in colorectal cancer
Lei Zhang et al.
NATURE (2018)
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
Takumi Maruhashi et al.
NATURE IMMUNOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
Yariv Mazor et al.
SCIENTIFIC REPORTS (2017)
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Chunhong Zheng et al.
CELL (2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Y. J. Bang et al.
ANNALS OF ONCOLOGY (2017)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Reversing T-cell Dysfunction and Exhaustion in Cancer
Hassane M. Zarour
CLINICAL CANCER RESEARCH (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody
Songmao Zheng et al.
MABS (2016)
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Xiaobo Mao et al.
SCIENCE (2016)
Insights into the molecular basis of a bispecific antibody's target selectivity
Yariv Mazor et al.
MABS (2015)
Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
Kathryn Baksh et al.
SEMINARS IN ONCOLOGY (2015)
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
Feng Xu et al.
CANCER RESEARCH (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies
Brian D. Harms et al.
METHODS (2014)
Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T- cells to Be Suppressed In Vivo
Nicholas M. Durham et al.
PLOS ONE (2014)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
Joseph F. Grosso et al.
JOURNAL OF IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II
Bitao Liang et al.
JOURNAL OF IMMUNOLOGY (2008)
LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems
Joseph F. Grosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
